Bionomics Limited (BNO) - Research

$0.1250.005 (3.85%)
Prices as at 16:40, 23 Apr 2019

BNO Current Share Price+

Current Price $0.125
Open $0.130
High $0.130
Low $0.125
Last Close $0.130
Volume 452330
Price Movement $0.01 ( 3.85% )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

BNO General Information

Bionomics Limited
BNO
http://www.bionomics.com.au
Biotechnology
68
545

BNO Company Overview

Business Description

Bionomics Limited (BNO) is an Australian biopharmaceutical company focused on the discovery and development of cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. BNO partners with pharmaceutical companies to get the drugs through the later stages of development and into the market.

BNO Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2020 F 0.00 -1.80 0.00% 0.00 0.00 0.00% 0.0%
2019 F 0.00 -3.60 0.00% 0.00 0.00 0.00% 0.0%
2018 A -25.09 -5.20 0.00% 0.00 0.00 0.00% 0.0%

BNO Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2018 A 2019 F 2020 F 2018 A 2019 F 2020 F 2018 A 2019 F 2020 F
Bionomics (BNO) $71M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL (CSL) $87,462M 0.3775 0.1269 0.1290 36.7746 32.6345 28.9045 1.60% 1.40% 1.61%
Clinuvel Pharmaceuticals (CUV) $1,195M 0.8671 0.0000 0.0000 91.3858 0.0000 0.0000 0.08% 0.00% 0.00%
Mesoblast (MSB) $773M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Polynovo (PNV) $602M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

BNO Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 3.70 0.00
Market 0.67 14.50 1.21 1.11
Sector 0.76 26.80 3.25 3.06

BNO Directors

Name Position Start Date
Dr Errol De Souza Executive Chairman, Executive Director 28 Feb 2008
Mr Alan David Fisher Non-Executive Director 1 Sep 2016
Mr Peter John Turner Non-Executive Director 16 Jun 2016
Mr David Ian Wilson Non-Executive Director 16 Jun 2016
Mr Mitchell D Kaye Non-Executive Director 23 Nov 2018

BNO Management

Name Position
Steven Lydeamore Chief Financial Officer
Jack Moschakis Company Secretary,Legal Councel
Paul Rolan Consultant Medical Officer Clinical Neuroscience

BNO Substantial Shareholders

Holding Name
49,147,193 (10.18%) BVF Partners L.P
39,115,389 (8.10%) Ausbil Investment Management Limited

BNO Calendar of Events

Date Event
14 February 2020 Report (Interim)
11 October 2019 Report (Annual)
15 August 2019 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.